Related Experiment Videos

Effects of monomethylfumarate on human granulocytes

P H Nibbering1, B Thio, T P Zomerdijk

  • 1Department of Infectious Diseases, University Hospital, Leiden, The Netherlands.

Insights

Monomethylfumarate (MMF), a metabolite of Fumaderm, enhances granulocyte functions crucial for fighting psoriasis. It boosts bacterial killing and elastase release while suppressing respiratory bursts, potentially explaining its therapeutic benefits.

Area of Science:

  • Immunology
  • Dermatology
  • Pharmacology

Background:

  • Psoriasis pathophysiology involves granulocytes.
  • Fumaderm is a new antipsoriasis drug with Monomethylfumarate (MMF) as its active metabolite.

Purpose of the Study:

  • Investigate the effects of MMF on granulocyte functional activities.
  • Determine the mechanisms behind MMF's action on granulocytes.

Main Methods:

  • Assessed granulocyte polarization, elastase release, and intracellular bacterial killing.
  • Measured FMLP-stimulated respiratory burst and FMLP receptor binding.
  • Monitored intracellular calcium ([Ca++]i) and cyclic adenosine monophosphate (cAMP) concentrations.

Main Results:

  • MMF stimulated granulocyte polarization, elastase release, and bacterial killing.
  • MMF suppressed FMLP-stimulated respiratory burst without affecting FMLP receptor binding.
  • MMF increased intracellular [Ca++]i and cAMP levels.

Conclusions:

  • MMF exhibits specific interactions with granulocytes, modulating their functional activities.
  • Increased [Ca++]i may mediate MMF's agonistic effects, while increased cAMP may mediate its antagonistic effects.
  • These granulocyte-modulating effects of MMF may contribute to its efficacy in treating psoriatic lesions.

Related Concept Videos